Sanara MedTech (SMTI) shares preliminary Q4 and full-year 2025 results

Rhea-AI Filing Summary

Sanara MedTech Inc. filed a current report to let investors know it has released a press release with certain preliminary financial results for the fourth quarter and full year 2025. The company states that this press release, dated January 23, 2026, is provided as an exhibit to the report and is incorporated by reference.

The company also clarifies that the information in this report, including the press release, is being furnished rather than filed, which means it is not subject to certain liability provisions of the securities laws or automatically incorporated into other securities filings unless specifically referenced.

false 0000714256 0000714256 2026-01-23 2026-01-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 23, 2026

SANARA MEDTECH INC.

(Exact name of registrant as specified in its charter)

Texas		001-39678		59-2219994
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1200 Summit Avenue, Suite 414 Fort Worth, Texas		76102
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (817) 529-2300

(Former name or former address, if changed since last report)

Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		SMTI		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On January 23, 2026, Sanara MedTech Inc. (the “Company”) issued a press release announcing certain preliminary financial results for the fourth quarter and full year 2025. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release issued January 23, 2026 (furnished pursuant to Item 2.02).
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 23, 2026
	Sanara MedTech Inc.
	By:	/s/ Elizabeth B. Taylor
		Name: Elizabeth B. Taylor
		Title: Chief Financial Officer

FAQ

What did Sanara MedTech Inc. (SMTI) disclose in this 8-K filing?

Sanara MedTech Inc. disclosed that it issued a press release announcing certain preliminary financial results for the fourth quarter and full year 2025, and it attached that release as an exhibit.

Which period do the preliminary results in the SMTI press release cover?

The preliminary results described in the press release cover the company’s fourth quarter and full year 2025.

How is the Sanara MedTech (SMTI) press release treated under securities laws?

The company states that the information in the report, including the press release, is furnished rather than filed, so it is not subject to Section 18 of the Exchange Act and is not automatically incorporated into other filings unless specifically referenced.

What exhibit did Sanara MedTech (SMTI) attach to this 8-K?

The company attached Exhibit 99.1, which is the press release issued January 23, 2026, describing certain preliminary financial results for the fourth quarter and full year 2025.

Who signed the Sanara MedTech Inc. (SMTI) 8-K report?

The report was signed on behalf of Sanara MedTech Inc. by Elizabeth B. Taylor, the company’s Chief Financial Officer.

On what date did Sanara MedTech (SMTI) issue the preliminary results press release?

Sanara MedTech issued the press release with preliminary financial results on January 23, 2026.